JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.28% |
| 2 | Technology | 15.04% |
| 3 | Healthcare | 12.52% |
| 4 | Financials | 10.55% |
| 5 | Consumer Discretionary | 7.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SNV
1701
DELISTED
Synovus
SNV
| $16.5M | ﹤0.01% |
458,677
+20,498
| +5% | +$848K |
2013 Q2
36 quarters
|
|
1702
Rivian
RIVN
$21.4B
| $16.5M | ﹤0.01% |
642,288
-480,449
| -43% | -$15M |
2021 Q4
2 quarters
|
|
1703
CALL
Philip Morris
PM
$293B
| $16.5M | ﹤0.01% |
167,000
-41,400
| -20% | -$4.22M |
2020 Q2
8 quarters
|
|
1704
Medpace
MEDP
$16.7B
| $16.5M | ﹤0.01% |
110,134
-7,674
| -7% | -$1.11M |
2017 Q3
19 quarters
|
|
1705
Bruker
BRKR
$9.44B
| $16.5M | ﹤0.01% |
262,499
+13,911
| +6% | +$853K |
2015 Q4
26 quarters
|
|
1706
PUT
Altria Group
MO
$112B
| $16.5M | ﹤0.01% |
394,100
+191,400
| +94% | +$9.91M |
2021 Q3
3 quarters
|
|
1707
PUT
Marathon Petroleum
MPC
$118B
| $16.4M | ﹤0.01% |
200,000
+163,300
| +445% | +$15.3M |
2021 Q3
3 quarters
|
|
1708
PUT
FedEx
FDX
$67.9B
| $16.4M | ﹤0.01% |
72,500
+40,000
| +123% | +$8.54M |
2020 Q3
7 quarters
|
|
|
LKFT
1709
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
| $16.4M | ﹤0.01% |
294,429
-5,281
| -2% | -$313K |
2019 Q1
13 quarters
|
|
1710
eGain
EGAN
$156M
| $16.4M | ﹤0.01% |
1,684,639
+543,228
| +48% | +$5.42M |
2017 Q4
18 quarters
|
|
|
CUK
1711
DELISTED
Carnival PLC
CUK
| $16.4M | ﹤0.01% |
2,078,373
+89,561
| +5% | +$1.21M |
2015 Q1
29 quarters
|
|
|
DOCU
1712
PUT
DocuSign
DOCU
$13B
| $16.4M | ﹤0.01% |
+286,000
| New | +$23.2M |
2022 Q2
0 quarters
|
|
|
SRRA
1713
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $16.4M | ﹤0.01% |
+298,323
| New | +$15.7M |
2022 Q2
0 quarters
|
|
1714
Polaris
PII
$2.98B
| $16.4M | ﹤0.01% |
165,151
+46,173
| +39% | +$4.78M |
2013 Q2
36 quarters
|
|
1715
Cloudflare
NET
$125B
| $16.4M | ﹤0.01% |
374,764
+220,741
| +143% | +$15.9M |
2019 Q3
11 quarters
|
|
1716
Markel Group
MKL
$21.4B
| $16.4M | ﹤0.01% |
12,670
-603
| -5% | -$827K |
2013 Q2
36 quarters
|
|
1717
LivaNova
LIVN
$4.12B
| $16.4M | ﹤0.01% |
262,062
-12,396
| -5% | -$878K |
2015 Q4
26 quarters
|
|
1718
Five Below
FIVE
$12.2B
| $16.4M | ﹤0.01% |
144,203
+16,851
| +13% | +$2.42M |
2015 Q3
27 quarters
|
|
1719
MYR Group
MYRG
$4.64B
| $16.4M | ﹤0.01% |
185,602
-17,945
| -9% | -$1.57M |
2016 Q3
23 quarters
|
|
1720
Tronox
TROX
$610M
| $16.3M | ﹤0.01% |
972,575
-166,003
| -15% | -$3.01M |
2015 Q3
27 quarters
|
|
1721
GATX Corp
GATX
$5.96B
| $16.3M | ﹤0.01% |
172,639
+104,079
| +152% | +$11.1M |
2013 Q2
36 quarters
|
|
1722
PUT
Thermo Fisher Scientific
TMO
$241B
| $16.2M | ﹤0.01% |
29,900
-9,000
| -23% | -$4.95M |
2021 Q2
4 quarters
|
|
1723
CALL
Deutsche Bank
DB
$66B
| $16.2M | ﹤0.01% |
1,858,400
-7,274,800
| -80% | -$77.7M |
2022 Q1
1 quarter
|
|
1724
Nelnet
NNI
$4.42B
| $16.2M | ﹤0.01% |
189,527
+106,758
| +129% | +$8.87M |
2013 Q2
36 quarters
|
|
1725
Inspire Medical Systems
INSP
$2.05B
| $16.1M | ﹤0.01% |
88,395
+18,424
| +26% | +$3.67M |
2018 Q2
16 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,728 reduced and 609 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 609 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.